Skip navigation

A trial looking at doxorubicin (Adriamycin) and cisplatin with or without paclitaxel (Taxol) for women with advanced womb (endometrial) cancer (EORTC 55984)

Please note this trial is no longer recruiting patients.

This trial is comparing 2 different chemotherapy regimes for advanced womb cancer.

Womb (endometrial) cancer can often be treated successfully with surgery. But sometimes the cancer comes back after initial treatment, or it is advanced when first diagnosed.

One of the treatments for women with advanced womb cancer is chemotherapy. Previous trials have shown that doxorubicin (Adriamycin) and cisplatin can work well together. This trial is trying to find out if adding another chemotherapy drug called paclitaxel (Taxol) will mean that the cancer is less likely to come back. The trial will compare these two groups of drugs

  • Doxorubicin (Adriamycin) and cisplatin
  • Doxorubicin (Adriamycin), cisplatin and paclitaxel (Taxol)

The researchers will also look at how the different combinations of drugs will affect quality of life.

Recruitment

Start 25/09/2002
End 05/09/2006

Phase

Phase 3

Who can enter

You can enter this trial if you

You cannot enter this trial if you

Trial design

This European trial will recruit 300 patients. The trial is randomised and there are two treatment groups. The people taking part are put into the different treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in.

If you are in group 1, you will have doxorubicin (Adriamycin) and cisplatin chemotherapy. You will have these drugs, as well as anti sickness drugs, through a drip into a vein in your arm. This will take about 2 hours. You will also have fluids through your drip before and after your treatment. This is one cycle of treatment, which is repeated every 3 weeks. You will have 6 cycles in total, so your treatment will take about 3 and a half months overall.

If you are in group 2, you will have doxorubicin (Adriamycin), cisplatin and pacitaxel (Taxol) chemotherapy. You will have these drugs, as well as anti sickness drugs, through a drip into a vein in your arm. This will take about 6 hours.

Before your chemotherapy you will have a steroid (dexamethasone) and anti histamine drug through the drip. This is to try to prevent possible side effects caused by paclitaxel (Taxol). You will also have fluids through your drip before and after your treatment. This is one cycle of treatment, which is repeated every 3 weeks. You will have 6 cycles in total, so your treatment will take about 3 and a half months overall.

Hospital visits

Before you start your treatment a doctor will examine you and do various tests. These will include

  • Blood tests
  • Chest X-ray
  • ECG
  • CT or MRI scan of your cancer.

You will have blood tests before each cycle of chemotherapy. The scan, chest x-ray and ECG will be repeated after the third and sixth cycle.

After your treatment finishes, you will continue to see a doctor

  • Every 3 months for the first 2 years
  • Every 6 months for the next 3 years
  • Every year after that

You will be examined by a doctor and some of the above tests will be repeated.

You will also fill out a questionnaire that will take about 10 minutes. This will ask how you have been feeling. It is called a ‘quality of life’ study. You complete these questionnaires before your treatment, after the 3rd cycle, 6th cycle and then every 6 months.

Side effects

All chemotherapy drugs have possible side effects. You can find out more about the side effects of doxorubicin (Adriamycin), cisplatin and paclitaxel (Taxol) on CancerHelp UK.

The most common side effects of these drugs are

Location of trial

CLOSED

For more information

The Information Nurses
Cancer Research UK
Angel Building
407 St John Street
London
EC1V 4AD

Tel: 0808 800 4040
Email: cancer.info@cancer.org.uk

Please note: we cannot help you to join a specific trial. Unless we state otherwise in this trial summary, you must go through your own doctor.

Chief Investigator

Dr N. Reed

Supported by

European Organisation for Research and Treatment of Cancer (EORTC)
National Cancer Research Network (NCRN)